---
$id: https://graph.org.ai/products/commodity/51111855
$type: Product
source: UNSPSC
code: "51111855"
title: "Lanreotide"
class: "51111800"
classTitle: "Hormones and antihormones"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Lanreotide

**UNSPSC Code**: 51111855
**Class**: [Hormones and antihormones](Hormones and antihormones.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a somatostatin receptor agonist with the molecular formula C54H69N11O10S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0G3DE8943Y, chemically known as l-threoninamide, 3-(2-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, cyclic (2-7)-disulfide but generally known as lanreotide, which bears US NIH Compound Identifier 71349. European Medicines Agency schedules Lanreotide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08402MIG. World Health Organization schedules lanreotide in its Anatomical Therapeutic Chemical (ATC) Classification. LANREOTIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lanreotide under HS 29349990 and SITC 51579. As of Q4 2014, LANREOTIDE remains the US FDA Preferred Term for this commodity. Lanreotide bears US NLM identifiers UMLS ID C0209211 and NCI Concept Code C1523. SMILES: S1SCC(NC(=O)C(N)CC2CC3C(CC2)CCCC3)C(=O)NC(C(=O)NC(CC2C3C([NH]C2)CCCC3)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(C1)C(=O)NC(C(O)C)C(=O)N)CC1CCC(O)CC1.

